secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2022-07-26T23:59:59+00:00
Accession:  0000950170-22-013078
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma receives $10M milestone from Merck after first patient dosed in Phase 1 collaboration study
--------------------------------------------------------------------------------

- Merck pays Sutro $10.0 million milestone following first patient dosing in Phase 1 study of a collaboration candidate.
- No other financial terms or guidance disclosed; collaboration continues.
- Specific investigational candidate not named in the filing.
- Milestone payment triggers positive cash inflow for Sutro's development programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022013078/0000950170-22-013078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017022013078/stro-20220726.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-013078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer